Search results
Showing 196 to 199 of 199 results for early or locally advanced breast cancer
NICE recommends olaparib for early breast cancer and metastatic prostate cancer
Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.